Attached files

file filename
EX-32.1 - EX-32.1 - ZIOPHARM ONCOLOGY INCd20446dex321.htm
EX-31.2 - EX-31.2 - ZIOPHARM ONCOLOGY INCd20446dex312.htm
EX-31.1 - EX-31.1 - ZIOPHARM ONCOLOGY INCd20446dex311.htm
EX-23.1 - EX-23.1 - ZIOPHARM ONCOLOGY INCd20446dex231.htm
EX-21.1 - EX-21.1 - ZIOPHARM ONCOLOGY INCd20446dex211.htm
EX-10.43 - EX-10.43 - ZIOPHARM ONCOLOGY INCd20446dex1043.htm
EX-10.42 - EX-10.42 - ZIOPHARM ONCOLOGY INCd20446dex1042.htm
EX-10.41 - EX-10.41 - ZIOPHARM ONCOLOGY INCd20446dex1041.htm
EX-10.40 - EX-10.40 - ZIOPHARM ONCOLOGY INCd20446dex1040.htm
EX-10.39 - EX-10.39 - ZIOPHARM ONCOLOGY INCd20446dex1039.htm
EX-10.20 - EX-10.20 - ZIOPHARM ONCOLOGY INCd20446dex1020.htm
EX-10.19 - EX-10.19 - ZIOPHARM ONCOLOGY INCd20446dex1019.htm
EX-10.17 - EX-10.17 - ZIOPHARM ONCOLOGY INCd20446dex1017.htm
EX-10.10 - EX-10.10 - ZIOPHARM ONCOLOGY INCd20446dex1010.htm
EX-10.9 - EX-10.9 - ZIOPHARM ONCOLOGY INCd20446dex109.htm
10-K - 10-K - ZIOPHARM ONCOLOGY INCd20446d10k.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ZIOPHARM Oncology, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy Cunningham, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Timothy Cunningham

Timothy Cunningham

Interim Chief Financial Officer

(Principal Financial Officer)

March 1, 2021